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Clinical and epidemiological investigations over the past 
25 years have signiﬁ cantly expanded our knowledge on 
invasive candidiasis in critically ill patients [1-4]. Pro-
longed exposure to multiple risk factors progressively 
increases the risk of developing invasive candidiasis from 
less than 5% to more than 15%. While early antifungal 
treatment has been suggested to improve clinical 
out come of this life-threatening complication, timely 
pros pec tive identiﬁ cation of patients who need pre-
emptive therapy aimed at minimizing both mortality and 
unnecessary prophylactic or empirical use of antifungals 
remains a major challenge for ICU physicians [5].
In contrast to positive Aspergillus cultures, which are 
highly predictive of invasive aspergillosis in profoundly 
immunocompromised patients, only a minority of 
critically ill patients with documented Candida coloniza-
tion will develop invasive infections [1-4]. Multiple 
approaches, including Candida colonization index [2], 
Candida scores and clinical prediction rules based on a 
combination of risk factors and colonization data [6,7], as 
well as molecular [8] and antigen/antibody blood assays, 
have been proposed for the early identiﬁ cation of ICU 
patients who are developing invasive candidiasis. 
A bstract
Invasive candidiasis is a frequent life-threatening complication in critically ill patients. Early diagnosis followed 
by prompt treatment aimed at improving outcome by minimizing unnecessary antifungal use remains a major 
challenge in the ICU setting. Timely patient selection thus plays a key role for clinically effi  cient and cost-eff ective 
management. Approaches combining clinical risk factors and Candida colonization data have improved our ability to 
identify such patients early. While the negative predictive value of scores and predicting rules is up to 95 to 99%, the 
positive predictive value is much lower, ranging between 10 and 60%. Accordingly, if a positive score or rule is used 
to guide the start of antifungal therapy, many patients may be treated unnecessarily. Candida biomarkers display 
higher positive predictive values; however, they lack sensitivity and are thus not able to identify all cases of invasive 
candidiasis. The (13)-β-D-glucan (BG) assay, a panfungal antigen test, is recommended as a complementary tool for 
the diagnosis of invasive mycoses in high-risk hemato-oncological patients. Its role in the more heterogeneous ICU 
population remains to be defi ned. More effi  cient clinical selection strategies combined with performant laboratory 
tools are needed in order to treat the right patients at the right time by keeping costs of screening and therapy as low 
as possible. The new approach proposed by Posteraro and colleagues in the previous issue of Critical Care meets these 
requirements. A single positive BG value in medical patients admitted to the ICU with sepsis and expected to stay 
for more than 5 days preceded the documentation of candidemia by 1 to 3 days with an unprecedented diagnostic 
accuracy. Applying this one-point fungal screening on a selected subset of ICU patients with an estimated 15 to 20% 
risk of developing candidemia is an appealing and potentially cost-eff ective approach. If confi rmed by multicenter 
investigations, and extended to surgical patients at high risk of invasive candidiasis after abdominal surgery, this 
Bayesian-based risk stratifi cation approach aimed at maximizing clinical effi  ciency by minimizing health care resource 
utilization may substantially simplify the management of critically ill patients at risk of invasive candidiasis.
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Colonization and clinical risk assessments are highly 
sensitive; how ever, their speciﬁ city is poor and positive 
predictive values ranging from 10 to 60% would imply 
that most patients with positive results would be treated 
in the absence of candidiasis. Th is would unnecessarily 
expose them to drug side eﬀ ects, select resistant Candida 
species and result in substantial health care resource 
utilization due to the high costs of antifungal agents [9]. 
Whereas biomarkers are more speciﬁ c, they would miss a 
high number of infections due to limited sensitivity 
[10,11]. Negative predictive values of up to 95 to 99% 
obtained with these clinical and laboratory tools in 
unselected groups of ICU patients at low risk of invasive 
candidiasis (less than 5%) do not thus allow eﬃ  cient 
identiﬁ cation of those who do not need antifungal 
therapy. Accordingly, none of these scores, rules or 
biomarkers is currently used for clinical decision-making 
at the bedside [5]. More eﬃ  cient clinical selection 
strategies combined with labora tory tools are thus 
needed in order to treat the right patients at the right 
time while keeping costs of screening and therapy as low 
as possible.
β-D-glucan (BG) is a panfungal cell wall component 
circulating in blood during invasive fungal infection. In 
recent meta-analyses its detection has been associated 
with variable diagnostic sensitivity and speciﬁ city, rang-
ing between 50 and 85% and 80 and 99%, respectively 
[12]. Based on its accuracy, experts recommend using BG 
for diagnosis to early detect invasive mycoses, both in 
clinical research and daily management in high-risk 
hemato-oncological patients [13]. Moreover, when 
compared with clinical, radiological and culture-based 
assessment, a study in acute leukemic patients has 
suggested that BG may anticipate diagnosis of invasive 
mycoses [10]. Due to a lack of clinical data, experts agree 
that its diagnostic role in the more heterogeneous ICU 
patient population remains to be deﬁ ned.
In this context, the study by Posteraro and colleagues 
[14] is an important step forward on the way to early 
identiﬁ cation of critically ill patients with invasive 
candidiasis. Th e diagnostic performance of BG anti-
genemia measured by the Fungitell® assay in medical ICU 
patients with sepsis was compared with that of Leon’s 
Candida score and Pittet’s colonization index. During a 
6-month period, 377 out of 450 (83.7%) consecutive ICU 
patients presented signs of sepsis and 95 of them (25%) 
were enrolled based on a length of ICU stay exceeding 5 
days and the absence of documented invasive fungal 
infection at time of screening and of any systemic 
antifungal treatment. Out of the 95 included patients, 16 
(16.8%) developed an invasive fungal infection: 14 (87.5%) 
were due to Candida, including 13 with candidemia.
Th e diagnostic accuracy was highest for a single 
positive BG value >80  pg/ml (receiver operating 
characteristic (ROC) area under the curve (AUC) 0.98), 
the cutoﬀ  recommended by the manufacturer, when 
compared with Candida score (0.80) and colonization 
index (0.63), respectively. Th e sensitivity of BG was 
93.7%, speciﬁ city 93.6%, positive predictive value 75%, 
and negative predictive value 98.6%. Moreover, BG detec-
tion preceded microbiological documentation of fungemia 
by 1 to 3  days. Th is impressive diagnostic per for mance, 
the best ever reported for a fungal biomarker in ICU 
patients, does probably reﬂ ect its use in strictly selected 
patients at high risk of candidemia. While a combination 
of BG and Candida score increased sensi tivity and 
negative predic tive value (both to 100%), speciﬁ city and 
positive predic tive value decreased (to 83.5% and 51.8%, 
respectively).
In addition, Posteraro and colleagues [14] provide 
important information for the routine use of BG. As 
environmental contamination resulting in false-positive 
results is a major issue, speciﬁ c precautions, including 
the use of BG-free materials, are recommended for blood 
sampling and processing. In the present study, BG 
measurements were compared in blood simultaneously 
drawn from peripheral venipuncture and via indwelling 
arterial catheters. Th e correlation between BG values 
measured in the two types of samples was excellent. Th is 
observation has important practical implications as it 
simpliﬁ es the bedside procedures without impacting on 
the accuracy of BG measurement.
Some limitations of this single-center study in candi-
demic medical ICU patients need to be addressed. Th e 
study does not provide data for surgical patients at high 
risk of deep-seated Candida infections without candi-
demia, mainly peritonitis after gastrointestinal tract 
surgery complicated by anastomotic leakage [1,4]. Th is 
well-deﬁ ned patient subgroup represents a substantial 
proportion of cases of invasive candidiasis in the ICU and 
might signiﬁ cantly beneﬁ t from early non-invasive 
diagnosis. In this setting, Candida colonization of multi-
ple body sites, absence of fungemia, and surgical gauze 
dressings as well as other multiple potential sources of 
environmental BG may all inﬂ uence the circulation of BG 
and thus impact on the diagnostic performance of the 
recommended test’s cutoﬀ  value. Th e low local incidence 
of bacterial bloodstream infections when compared with 
the high incidence of fungemia suggests that the results 
obtained in the study setting might not apply to ICUs 
with diﬀ erent epidemiological backgrounds. Last but not 
least, this observational study does not provide any 
information on the impact on patient outcome of inte-
grat ing BG in real-time clinical management decisions.
In conclusion, this proof-of-concept study in invasive 
candidiasis opens the way to a new sequential approach 
for risk stratiﬁ cation in critically ill patients. With a 
Bayesian approach based on straightforward clinical 
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criteria for identiﬁ cation of medical ICU patients at high 
risk of developing candidemia, the intrinsic speciﬁ city of 
BG results in high diagnostic accuracy of a single positive 
test [15]. Provided that the hospital lab is able to provide 
results to clinicans within 12 to 24 hours, BG antigenemia 
would prompt the start of pre-emptive antifungal 
therapy. Alternatively, empirical antifungal therapy may 
be discontinued as soon as negative BG and blood culture 
results are available. However, demonstration of the re-
pro ducibility of this sound and appealing unprecedented 
observation in diﬀ erent hospitals and patient settings is 
needed. In particular, the utility of BG in patients at high 
risk of invasive candidiasis after complicated abdominal 
surgery needs to be investigated, as it might have a 
signiﬁ cant impact on therapeutic decisions and out-
comes. Should these results be conﬁ rmed, this very 
attractive, simple and inexpensive approach may repre-
sent a major advance in the management of critically ill 
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